Objective To analyze the efficacy and safety of Aidi injection in the adjuvant treatment of advanced colorectal cancer.Methods Forty-seven patients with advanced colorectal cancer admitted to the Department of Oncology and Hematology in Anyang Anyang Workers General Hospital from June 2019 to January 2024 were divided into two groups by random number table method. Control group (23 cases) received oxaliplatin + capecitabine chemotherapy. The study group (24 cases) was treated with Aidi injection on the basis of the control group. Clinical efficacy, tumor marker levels (carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA)) and adverse drug reactions of the two groups were analyzed and compared.Results There was no significant difference in the total effective rate between the two groups (P > 0.05). Before treatment, there were no significant differences in the levels of tumor markers CA125, CA19-9 and CEA between two groups (P > 0.05). After treatment, the levels of tumor markers CA125, CA19-9 and CEA in both groups were significantly lower than before treatment, and the levels of tumor markers in the study group after treatment were lower than those in the control group (P < 0.05). There was no significant difference in the adverse reaction rate between the two groups (P > 0.05).Conclusion Addy injection can improve the curative effect and is safe and reliable for patients with advanced colorectal cancer.